Leprosy vaccine is under clinical development by HDT Bio and currently in Phase I for Leprosy. According to GlobalData, Phase I drugs for Leprosy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Leprosy vaccine LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Leprosy vaccine overview
Vaccine candidate is under investigation for the prevention of leprosy. The vaccine candidate comprises of recombinant four-antigen Mycobacterium leprae antigen LEP-F1 in combination with the adjuvant formulation GLA-SE (glucopyranosyl lipid A). It is administered by intramuscular route.
See Also:
HDT Bio overview
HDT Bio is a biopharmaceutical company that discovers and develops treatments for cancers and infectious diseases. It is investigating HDT-301 vaccine to prevent COVID-19; HDT-311 against infectious diseases; HDT-211 for the treatment of cancer. The company is also evaluating HDT-401 targeting head and neck cancer; and HDT-104 to treat ovarian cancer. HDT Bio utilizes its proprietary lipid nanoparticle (LION) platform, an RNA (ribonucleic acid) delivery technology that stabilizes, protects, and transports RNA during formulation and administration to enable immune stimulants and disease antigens reach target cells for expression. It works in collaboration with Gennova Biopharmaceuticals Ltd, Senai Cimatec, Quratis Inc, University of Washing ton, and other companies. HDT Bio is headquartered in Seattle, Washington, the US.
For a complete picture of Leprosy vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
